<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>雷贝拉唑片剂 &#8211; 元哲咨询</title>
	<atom:link href="https://www.yuanzhezixun.com/tag/leibeilazuopianji/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.yuanzhezixun.com</link>
	<description>行业研究专家</description>
	<lastBuildDate>Wed, 15 Dec 2021 02:10:01 +0000</lastBuildDate>
	<language>zh-Hans</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	

<image>
	<url>https://www.yuanzhezixun.com/wp-content/uploads/2021/10/cropped-shcrilogo-c-45x45.jpg</url>
	<title>雷贝拉唑片剂 &#8211; 元哲咨询</title>
	<link>https://www.yuanzhezixun.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>2021-2025年中国雷贝拉唑市场研究报告(中文版含税价人民币12,000元)</title>
		<link>https://www.yuanzhezixun.com/2021-2025nianzhongguoleibeilazuoshichangyanj/</link>
		
		<dc:creator><![CDATA[Timlee]]></dc:creator>
		<pubDate>Tue, 08 Jun 2021 07:22:32 +0000</pubDate>
				<category><![CDATA[医/药/保健]]></category>
		<category><![CDATA[报告速递]]></category>
		<category><![CDATA[行业资讯]]></category>
		<category><![CDATA[JUMPCAN]]></category>
		<category><![CDATA[PARIET]]></category>
		<category><![CDATA[佐森格埃利森综合症]]></category>
		<category><![CDATA[十二指肠溃疡]]></category>
		<category><![CDATA[卡佩莱]]></category>
		<category><![CDATA[卫材]]></category>
		<category><![CDATA[奥加明]]></category>
		<category><![CDATA[奥赛康药业]]></category>
		<category><![CDATA[波利特]]></category>
		<category><![CDATA[济川药业]]></category>
		<category><![CDATA[济诺]]></category>
		<category><![CDATA[澳博平]]></category>
		<category><![CDATA[罗欣药业]]></category>
		<category><![CDATA[胃药]]></category>
		<category><![CDATA[胃酸抑制剂]]></category>
		<category><![CDATA[质子泵抑制剂]]></category>
		<category><![CDATA[长澳制药]]></category>
		<category><![CDATA[雷贝拉唑]]></category>
		<category><![CDATA[雷贝拉唑注射剂]]></category>
		<category><![CDATA[雷贝拉唑片剂]]></category>
		<category><![CDATA[雷贝拉唑肠溶胶囊]]></category>
		<guid isPermaLink="false">http://www.yuanzhezixun.com/?p=24268</guid>

					<description><![CDATA[CRI元哲的调研数据显示，2016-2019年中国雷贝拉唑市场销售额逐年增加。由于新冠疫情对医疗整体诊疗服务的冲击，2020年的销售额有所减少<div class='yarpp yarpp-related yarpp-related-rss yarpp-related-none yarpp-template-list'>

没有相关文章
</div>
]]></description>
		
		
		
			</item>
	</channel>
</rss>
